Rottinghaus Scott T.
Chief Medical Officer
Rottinghaus Scott T. has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Aug 10, 2026.
On the most recent filing, Rottinghaus Scott T. is listed as Chief Medical Officer at ENANTA PHARMACEUTICALS INC. Inside the rolling window, Rottinghaus Scott T. reported no open-market purchases and 1 open-market sale totaling $11K in ENTA.
Companies traded
Other insiders at ENTA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$11K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Rottinghaus Scott T. made?
Rottinghaus Scott T. has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Rottinghaus Scott T. trade?
Rottinghaus Scott T. has filed SEC Form 4 disclosures for 1 company, including ENTA.
When was Rottinghaus Scott T.'s most recent SEC Form 4 filing?
Rottinghaus Scott T.'s most recent SEC Form 4 filing on Tracefour is dated Aug 10, 2026.
What is Rottinghaus Scott T.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Rottinghaus Scott T. is listed as Chief Medical Officer.
What is Rottinghaus Scott T.'s total buy and sell value in the current window?
Inside the rolling retention window, Rottinghaus Scott T. bought $0 and sold $11K based on SEC Form 4 filings.
What was Rottinghaus Scott T.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 798 ENTA shares on 2025-12-05, worth $11K, per SEC Form 4 filings.